A phase 1/2 trial reported durable hematologic and metabolic responses from a dual-targeting BCMA and CD19 CAR T approach in heavily pretreated relapsed or refractory multiple myeloma, including patients with extramedullary disease. The update emphasizes response depth and durability in a patient group with historically poor outcomes. The study’s focus on high-risk disease settings suggests dual targeting may help mitigate antigen escape mechanisms that can limit single-target CAR-T durability. For biotech teams, this provides new data supporting continued development and optimization of multi-antigen CAR-T constructs. Stakeholders will want to watch for safety signals, durability at longer follow-up, and whether these results translate into registrational endpoints in future study designs.